Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Abivax SA is a clinical-stage biotechnology company that develops therapeutics designed to harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Headquartered in Paris, France, and founded in 2013, the company operates in both France and the United States, with research activities centered on immune modulation for inflammatory disorders. Abivax SA’s core focus is on inflammatory bowel diseases, particularly ulcerative colitis and Crohn’s disease, where it aims to address moderate to severe forms of these conditions through advanced biologically targeted therapies. Its lead product candidate, obefazimod, is an orally administered small molecule in late-stage clinical development for ulcerative colitis and mid-stage trials for Crohn’s disease, acting via enhanced expression of microRNA-124, a key regulator of inflammatory pathways. Within the healthcare and biotechnology sector, Abivax SA plays a specialized role as an R&D-driven enterprise advancing novel immunoregulatory approaches for chronic inflammatory diseases.